Vis enkel innførsel

dc.contributor.authorTraaen, Gunn Marit
dc.contributor.authorAakerøy, Lars
dc.contributor.authorHunt, Tove Elisabeth F.
dc.contributor.authorØverland, Britt
dc.contributor.authorLyseggen, Erik
dc.contributor.authorAukrust, Pål
dc.contributor.authorUeland, Thor
dc.contributor.authorHelle-Valle, Thomas Michael
dc.contributor.authorSteinshamn, Sigurd Loe
dc.contributor.authorEdvardsen, Thor
dc.contributor.authorZare, Hasse Khiabani
dc.contributor.authorAakhus, Svend
dc.contributor.authorAkre, Harriet
dc.contributor.authorAnfinsen, Ole-Gunnar
dc.contributor.authorLoennechen, Jan Pål
dc.contributor.authorGullestad, Lars
dc.date.accessioned2019-08-27T09:29:14Z
dc.date.available2019-08-27T09:29:14Z
dc.date.created2019-03-26T15:20:38Z
dc.date.issued2018
dc.identifier.citationScandinavian Cardiovascular Journal. 2018, 52 (6), 372-377.nb_NO
dc.identifier.issn1401-7431
dc.identifier.urihttp://hdl.handle.net/11250/2611146
dc.description.abstractRationale. Atrial fibrillation is associated with increased mortality as well as morbidity. There is strong evidence for an association between atrial fibrillation and sleep apnea. It is not known whether treatment of sleep apnea with continuous positive airway pressure (CPAP) will reduce the burden of atrial fibrillation. Objective. The Treatment of Sleep Apnea in Patients with Paroxysmal Atrial Fibrillation study will investigate the effects of CPAP in patients with paroxysmal atrial fibrillation and sleep apnea. Design: The trial has a dual center, randomized, controlled, open-label, parallel design. Methods. Two centers will enroll a total of 100 patients with both paroxysmal atrial fibrillation and sleep apnea (apnea-hypopnea index [AHI] 15 events/h) who are scheduled for catheter ablation. Patients will be randomized in a 1:1 ratio to CPAP or control group (50 patients in each arm). The effects of CPAP treatment on atrial fibrillation will be determined using an implanted loop recorder (Reveal LINQTM, Medtronic) that detects all arrhythmia episodes. The primary endpoint is a reduction of the total burden of atrial fibrillation in the intervention group, after 5 months’ follow-up (preablation). Reduction in the arrhythmia recurrence rate after ablation is the main secondary endpoint. All patients will be followed up for 12 months after ablation. Conclusion. This study is the first randomized controlled trial that will provide data on the effects of CPAP therapy in patients with paroxysmal atrial fibrillation and sleep apnea. The results are expected to improve our understanding of the interaction between paroxysmal atrial fibrillation and sleep apnea.nb_NO
dc.language.isoengnb_NO
dc.publisherTaylor & Francisnb_NO
dc.titleTreatment of sleep apnea in patients with paroxysmal atrial fibrillation: design and rationale of a randomized controlled trialnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.pagenumber372-377nb_NO
dc.source.volume52nb_NO
dc.source.journalScandinavian Cardiovascular Journalnb_NO
dc.source.issue6nb_NO
dc.identifier.doi10.1080/14017431.2019.1567933
dc.identifier.cristin1687920
dc.description.localcodeThis article will not be available due to copyright restrictions. © 2019 Informa UK Limited, trading as Taylor & Francis Groupnb_NO
cristin.unitcode194,65,25,0
cristin.unitnameInstitutt for sirkulasjon og bildediagnostikk
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel